85% of targeted hazardous waste is sent for Co-Processing for use as alternate fuel

31% Reuse of treated wastewater out of total wastewater generated (2,98,804 KL)
2,26,969 tCO2e emissions avoided through energy-saving initiatives

The amount of waste produced worldwide is 4 billion metric tonnes each year and expected
to double by 2025 owing to economic and population growth. About 70 percent of this is
dumped into landfills or open dumps. Each type of waste creates different hazards,
adversely impacting the health of communities and ecosystems alike.

Our strategy is to handle each stream of waste with specific solutions, thus managing and
disposing waste with minimum impact. We have focused on four waste streams including
hazardous waste, non-hazardous waste, e-waste and domestic waste from our facilities.

HAZARDOUS WASTE AND CO-PROCESSING

At Glenmark we pursue best in industry practices for disposal of hazardous waste.

Our target is to reduce the waste generated and to devise innovative ideas to send zero
hazardous waste in to the landfill. We have initiated this process by co-processing the
Hazardous waste. Our plants like Goa, Indore, Baddi, Sikkim are engaged in Pre-processing &
Co-processing of Hazardous waste and aiming to achieve 100% disposal of Hazardous waste
through cement kilns.

DOMESTIC WASTE
Glenmark understands the importance of segregation of waste at source. By doing so, we
not only salvage valuable material present in the waste but also divert this waste from going
into landfills. It also helps reduce greenhouse gas emissions that are otherwise emitted if
not composted. In our facilities, segregated waste is converted into manure via
vermicomposting.
E-WASTE
We at Glenmark understand the importance of conserving virgin natural resources and our
commitment towards this cause is evident from the numerous initiatives that we have
undertaken. Our offices are a constant source of waste, especially e-waste We have reduced
the amount of e-waste going to landfills by encouraging refurbishment and reuse of
electronic components.

While e-waste has been a source of livelihood for the urban poor, it is often one of the
major contributing factors for severe risks to human health and the environment. Most
workers engaged in the waste sector are not aware of the risks involved. The practices
adopted in recycling waste and recovering materials are rudimentary, involving acid bath
heating, open burning and indiscriminate use of chemicals without following any safety
norms. These are often conducted in the by lanes of the city, making them dangerous and
hazardous for the environment and human health.

By sending the e-waste to authorised recyclers we are assured of safe disposal of the e-
waste generated in our offices, plants and R&D sites, thereby reducing the environmental
pollution and health risks to the society.

We at Glenmark have promoted resource efficiency through waste management in an

environmentally safe and socially responsible manner by adopting a combination of
treatment options. These include e-waste recycling, in-house composting, hazardous
waste co-processing, coupled with creating awareness through various environmental
campaigns.

MANAGEMENT OF WASTE SOLVENT

Scarcity of resources is driving the need for efficient use. Our commitment to conserving
natural resources includes making best use of all materials. At Glenmark, we recover the
solvent used in our processes for material efficiency and resource recovery. Pharmaceutical
processes require solvent as a medium for separation and purification, washing of product
and cleaning of equipment. Significant quantity of the spent solvent is generated from these
processes. Such a large volume of spent solvent cannot be reused without decontamination.

Solvent recycling in API facilities is possible after quality assurance unlike other
manufacturing facilities that strictly avoid recycling of materials. Spent solvent disposal to
the environment is not advised as it can be toxic and non-biodegradable. Recovering good
quality solvent for recycling in API manufacturing process is also a challenge as it requires
complex design and large set up to remove various contaminants present in the spent
solvent.

Privacy Notice - Glenmark Pharmaceuticals

Quality at Glenmark

At Glenmark, quality is of paramount importance and stringent checks go into every product
we manufacture. Our principles of excellence and the emphasis to ensure a culture of
uncompromising quality, has earned us a remarkable reputation with our customers and
regulatory agencies around the globe. This is reflected in the multiple accolades and
recognitions conferred on us over the years. We have 14 state-of-the-art manufacturing
facilities that are inspected by various regulatory bodies such as the US-FDA, MHRA UK,
WHO-GMP, Canadian TPD, South African MCC and ANVISA of Brazil. At Glenmark, we are
relentless in stepping up our quality systems across our research and manufacturing
facilities, ensuring that our products, processes and infrastructure – all measure up to
international expectations.

Formulations

Our extensive range of finished dosage formulations covers every aspect of human life. Our
basket of formulations contains more than 850 products in several forms belonging to 45
therapeutic segments and 12 specialties including cardiovascular, gastrointestinal,
analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics,
immunologicals and oncology. Our formulation business fulfils the need for domestic,
regulated, and rest of the world markets.

Our globally accredited, state-of-the-art manufacturing facilities in Dholka (Gujarat), Samba

(Jammu and Kashmir) and Addis Ababa (Ethiopia) produce almost all dosage forms including
sterile as well as non-sterile products.

Cipla Sustainability | Cipla

We have also undertaken initiatives to serve and support the community in response to the
COVID-19 pandemic.

During the pandemic, we stood by the most underserved communities, reaching out to
10,00,000+ people across India. Staying true to our purpose-driven and socially conscious
legacy of ‘Caring for Life,’ we supported several initiatives. This included working with the
Government of India, local administration, healthcare workers and NGOs.

Business Model - The Madras Pharmaceuticals- product importance.

Quality - The Madras Pharmaceuticals
lotus_csr_policy.pdf (lotuslabs.com)- this is corporate social responsibility pdf

Determining materiality of product

The report provides information of material significance to our stakeholders in creating
short and long-term value across our business. For this reporting year, we have identified
thirty-nine areas that are of priority to the nature of our business and categorized them into
six assemblies. After in-depth research and review, the material areas have been identified
from the Sustainability Accounting Standards Board (SASB) and the MSCI ESG guidance
documents and frameworks. These material areas were confirmed after a process of
prioritization and through a materiality assessment with the senior management.

Quality. One destination. Two paths.

 Our teams follow Good Manufacturing Practices (GMP) across product cycles, with
constant upgradations in technology, such as Laboratory Information

 An integrated risk-based management system at our plants uphold our Quality by

Design initiative to enhance the safety and efficacy of our products.
Why our product needs to be trusted-
At Laurus Labs, we are a fully integrated pharmaceutical and biotechnology company, with
a leadership position in Active Pharmaceutical Ingredients (APIs) in selected high-growth
therapeutic areas and major focus on anti-retroviral, Hepatitis C, and oncology drugs. Today,
we are one of the leading suppliers of APIs in the ARV therapeutic area for multinational
pharmaceutical companies across different parts of the globe.
. Most of our manufacturing facilities are approved by major regulatory authorities, USFDA,
WHOGeneva, UK-MHRA, etc. Our approach remains to identify and invest ahead of time
with strategic investments in state of-the-art R&D and manufacturing infrastructure,
enabling us to become a quality supplier in the products we chose.
Being a fully integrated player, we have a natural advantage and a superior margin profile
compared to non-integrated players. At present, we are supplying APIs to most of the
players who participate in ARV tenders in the Low and Middle Income Countries (LMIC). We
have also acquired Aspen's South African subsidiary to get a foothold in the world's largest
generic-accessible ARV market.
Our products
We work closely with leading innovators, global health organizations, and providers, without
compromising quality standards keeping our core philosophy of “One Quality Standard for
All Markets”.
At Laurus Labs, we have dealt in 60+ commercialised products since inception across four
distinct business units: Laurus Generics API and finished dosage forms (FDF), Laurus
Synthesis and Laurus Bio Being one of our core competencies, we offer a comprehensive
range of APIs in the oncology segment.
We are continuously extending our portfolio by focusing on products in diabetes,
ophthalmology, and cardio-vascular therapy areas, where we can make a difference and
establish a leadership position. We offer our globally compliant cGMP facilities, along with
our chemistry expertise, to customers for contract development and manufacturing of APIs
and intermediates.
We also manufacture safe and effective natural ingredients for weight management, sports
nutrition, joint health, metabolic disorders, eye health, skin care, and general wellbeing. Our
Ingredients division offers Contract Development and Manufacturing services for
Nutraceutical clientele through manufacturing procedures that conform to the international
compliance standards prescribed by GMP, Kosher, Halal and HACCP, etc.
How we develop product
We develop and manufacture oral solid formulations, provide Contract Research and
Manufacturing Services (CRAMS) and Contract Development and Manufacturing
Organisation (CDMO) to esteemed global pharmaceutical companies. As a CRAMS partner to
several customers, we follow stringent quality and EHS systems, wide operability range
(from grams to multi-tonnage scale) and robust project management practices. The
Company is pleased to announce that it has recently received the licence from Defence
Research & Development Organisation (DRDO) to manufacture and market 2- Deoxy-D-
Glucose (2DG) used in the management of SARS-2 Coronavirus
We run with SDGS 8, 17, 7, 9, 13,3

Why our product is natural?

Solar power panels installed (total energy consumed: 66877 KWh)), received approvals from
USFDA, TGA, MHRA, KFDA, WHO-Geneva, PMDA, NIP-Hungary, COFEPRIS -Mexico, MIT –
Russia, ANVIS
We use solar plants.
Quality control
Our dedicated quality and regulatory teams provide technical and market support for all
regulatory affairs. Additionally, our manufacturing facilities comply with the requirements of
Integrated Management System (IMS), strictly following ISO 9001-2015: Quality
management System, ISO 14001-2015: Environment Management System and ISO 45001-
2018: Occupational health and Safety Assessment system standards.
Ensuring quality:
• Receipt, Storage and Handling of Raw Materials: Raw materials are verified at the
warehouse through necessary documentation, approvals, etc.
• Manufacturing Facilities: We have well designed facilities for the manufacturing, testing,
storage of the products for meeting the regulatory and cGMP requirements.
• Quality Control Department: We have well designated facilities and well-trained
personnel and procedures available for sampling, inspecting, and testing of raw materials,
packing materials, intermediates, API, finished products and monitoring of environmental
conditions.

• Quality Assurance: We have a well-established quality assurance system to release or

reject raw materials, packing materials, inprocess materials, intermediates, APIs and
finished Goods. In addition, we also use electronic quality assurance management software
for handling quality management systems.
Learning management system software for handling training. • Quality Review meeting &
Safety committee meeting – Monthly reviews and inspections are conducted to look out for
any quality and safety related issues respectively.
Our partners for sustainable environment
Confederation of Indian Industry We engage with both potential and existing customers on
a regular basis in order to comprehend the changing nature of market requirements Laurus
Labs – Integrated Report FY 2021 Page 71 ”
● Pharmaceuticals Export Promotion Council of India
● The Federation of TG and AP Chambers of Commerce &
● Industry (FTAPCCI)
● Bulk Drugs Manufacturers Association
● JNPC Manufacturers Association
● The Associated Chambers of Commerce & Industry of India
Indo American Chamber of Commerce, Hyderabad
● Indian Drug Manufacturers Association
● Federation of Indian Chambers of Commerce and Industry
Emissions
At Laurus Labs, we understand the imperative to reduce Greenhouse Gas (GHG) emissions
in our operations. Our GHG emissions are generated from diesel, natural gas, furnace oil
(residual fuel oil) and electricity consumption. We were able to significantly reduce GHG
emissions with the support of our renewable energy programmes, in addition to an overall
reduction in GHG emissions through conventional energy sources. We have used the
Intergovernmental Panel on Climate Change (IPCC) AR 4 emission factors for fuels [Global
warming potential (GWP), as per AR 5] and CEA (Central Electricity Authority) emission
factors for grid electricity in India. We have also used country-specific emission factors for
our electricity consumption in other countries. As we work towards slowly reducing our
emissions, in FY 2021 we experienced in 19% increase in our total emissions from 2,67,117
tCO2 to 3,16,625 tCO2, vis a vis a 54% increase in our revenue for Units 1 and 3. Further, our
GH intensity (tCO2/MT) has reduced by 35% from 221 tCO2/MT to 143 tCO2/MT since the
last financial year.
Waste and effluent
Wastewater is segregated into high total dissolved solids (HTDS) and low total dissolved
solids (LTDS) water before being sent to the common effluent treatment plant (CETP) where
it is further treated and disposed as per statutory guidelines. The toxic waste is intoxicated
within the facility before disposal and the hazardous and nonhazardous solid waste is
segregated at source.
Through our focused yield improvement programs, we continue to minimise our waste and
improve operational efficiency. In FY 2020-21, there were yield improvements to the extent
of 3%-10% in five different products. During the reporting period, there were no spills
reported. All nonhazardous waste, such as metal scrap, paper, etc. were sent to recyclers.
Some of the active measures and interventions to reduce processed waste from our
operations are:
• ATDF-2 process effluent generation reduced @12 KL per batch i.e., FY-2020-2021:
2,19,000
• By installing electrolytic water treatment system for cooling tower: 2,190 KL
• All used batteries are returned to the supplier or recycler. E-waste is collected and
delivered to authorised recyclers
• In FY 2020-21 100% of the hazardous waste produced was disposed safely across units 1
and 3

Tablets India quality benchmark is achieved by strict adherence to the following:

 Well-designed cGMP/ ISO compliant QMS to ensure quality right the first time and
every time.
  Authorised lab for QC tests accredited by Govt certification.
 Excellent Quality Control parameters followed.
 World Class Quality Assurance that approves and reviews procedures for every
activity/ process that has a bearing on quality.
 Maintains master procedure of SOP, Qualification, Validation, CCP and DDC. Also
ensures compliance to regulatory needs.

We take care of
Development of product
Quality needs to be built into the product. The aim of pharmaceutical development is to
design a quality product and its manufacturing process to consistently deliver the intended
performance of the product. The information and knowledge gained from pharmaceutical
development studies provides clear scientific understanding to support the establishment of
specifications and manufacturing controls which will thereafter enable to ensure a
pharmaceutical product’s quality throughout its life cycle. 
Distribution

Any comprehensive system of quality assurance must be founded on a reliable system of

controlling the quality, safety and efficacy of a finished product delivered to a market. It is
imperative that all manufacturing operations are carried out in conformity with the
accepted norms of GMP. 

The distribution channel and supply chain need to follow quality assurance as well in order
that patients are getting quality medicines. WHO has issued international standards assisting
Member States and those involved in the supply chain. 
Inspections

Inspections are part of the overall quality management system. The objective of inspecting

pharmaceutical manufacturing facilities is either to enforce Good Manufacturing Practice
(GMP) compliance or to provide authorization to manufacture specific pharmaceutical
products, usually in relation to an application for marketing authorization. A further aspect
of pharmaceutical inspection is monitoring the quality of pharmaceutical products in
distribution channels, from the point of manufacture to delivery to the recipient, as a means
of eliminating the hazard posed by the infiltration of falsified medicines. 

Quality control guidelines

The term “quality control” refers to the sum of all procedures undertaken to ensure the
identity and purity of a particular pharmaceutical. Such procedures may range from the
performance of simple chemical experiments which determine the identity and screening
for the presence of particular pharmaceutical substances (e.g. thin layer chromatography,
infrared spectroscopy, and so on), to more complicated requirements of pharmacopoeial
monographs. Activities extend to the area of quality control laboratories (e.g. good
laboratory management practices, models, for example for certificates of analysis and lists
of laboratory equipment, and an external assessment scheme). 

Regulatory standards

WHO has formulated international regulatory standards, which include stability, packaging,

storage, and bioequivalence. Care must be taken to ensure that active pharmaceutical
compounds remain stable and unaffected by packaging materials or storage conditions.
Further, the establishment of bioequivalence standards between originator
and generic medicines is of great importance given WHO's support of generic products and
their potential to increase access to essential medicines.

Quality assurance is given.

Planting trees and promoting ecological balance to increase green cover is the most
practiced custom at Divi’s to protect our society and maintain ecological balance.
The impact of such plantation drives has improved the oxygen cover for the local population
in the villages.
 
Plantation Covered FY2021-22:
 Villages Covered: 35
 Number of Plantations: ~1,37,000

Biocon has implemented several initiatives on clean technology, energy efficiency,

renewable energy at its sites, including:

 Installation of energy efficient centrifugal air compressors;

 Installation of LED lighting to replace fluorescent lamps;
 Power Trading through Indian Energy Exchange;
 Installation of energy efficient air blower motors;
 Reduction in CO2 emissions by using PNG (Piped natural gas) for steam generation;
  53% of total power requirement is sourced from renewable energy sources. The
continuous adoption of renewable energy as a preferred source has enabled us to
increase its share in our total power consumption to more than half for the first time
this fiscal year;
 Installation of solar powered lighting;
 Installation of waste steam recovery system;
 Installation of two stage scrubber system at multiple effect evaporator system to
ensure better air quality in and around a facility.
 Air emissions and waste generated by the Company are well within the permissible
limits prescribed by the environmental regulators

Some of the striking features that have allowed us to remain ahead of our competitors
include:

 Rich Experience
 GMP & WHO Manufacturing Collaboration
 Wide range of products approved by DCGI
 State-of-the-art Manufacturing Collaboration
 Spacious Warehouse
Our Quality Assurance
Click to Zoom
Being a quality-oriented name of the industry, we are committed to manufacture, trade,
wholesale and supply a comprehensive range of highly effective Pharmaceutical Medicines
& Injections. Offered medicines are formulated using finest quality active ingredients and
chemical compounds. While formulation of these medicines, we follow FDA laid standards
and norms.

Various parameters on which the quality inspection of the product is done include
following:-

 Purity
 Effectiveness
 Stability

EHSPolicy.pdf (zyduslife.com)- environment policy